Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK - PubMed
5 hours ago
- #targeted therapy
- #endometrial cancer
- #clinical trial
- The COPELIA trial compared cediranib plus weekly paclitaxel or olaparib versus weekly paclitaxel alone in advanced or recurrent endometrial cancer patients previously treated with platinum-based chemotherapy.
- Paclitaxel plus cediranib significantly improved 3-month progression-free survival (PFS) and RECIST response rates compared to paclitaxel alone, but this benefit diminished over time with no differences in 6-month PFS, median PFS, or median overall survival.
- Cediranib plus olaparib did not show significant improvements over paclitaxel alone in 3-month PFS or RECIST response.
- Adverse events like hypertension, neutropenia, and diarrhea were more common with cediranib combinations, and quality of life was worse for diarrhea and gastrointestinal symptoms compared to paclitaxel alone.
- A reduction in plasma Tie2 (a vascular response biomarker) within 9 weeks was associated with improved PFS in cediranib-treated patients, suggesting its potential as a predictive biomarker.